Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2013

Open Access 01-12-2013 | Review

A diverse array of genetic factors contribute to the pathogenesis of Systemic Lupus Erythematosus

Authors: Nicki Tiffin, Adebowale Adeyemo, Ikechi Okpechi

Published in: Orphanet Journal of Rare Diseases | Issue 1/2013

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with variable clinical presentation frequently affecting the skin, joints, haemopoietic system, kidneys, lungs and central nervous system. It can be life threatening when major organs are involved. The full pathological and genetic mechanisms of this complex disease are yet to be elucidated; although roles have been described for environmental triggers such as sunlight, drugs and chemicals, and infectious agents. Cellular processes such as inefficient clearing of apoptotic DNA fragments and generation of autoantibodies have been implicated in disease progression. A diverse array of disease-associated genes and microRNA regulatory molecules that are dysregulated through polymorphism and copy number variation have also been identified; and an effect of ethnicity on susceptibility has been described.
Appendix
Available only for authorised users
Literature
1.
Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med. 2008, 358 (9): 929-939. 10.1056/NEJMra071297.PubMedCrossRef
2.
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8 (6): 492-502. 10.1038/sj.gene.6364408.PubMedCentralPubMedCrossRef
3.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349 (16): 1526-1533. 10.1056/NEJMoa021933.PubMedCrossRef
4.
Pathak S, Mohan C: Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. Arthritis Res Ther. 2011, 13 (5): 241-10.1186/ar3465.PubMedCentralPubMedCrossRef
5.
6.
Fessel WJ: Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med. 1974, 134: 1027-1035. 10.1001/archinte.1974.00320240061006.PubMedCrossRef
7.
Danchenko N, Satia JA, Anthony MS: Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006, 15 (5): 308-318. 10.1191/0961203306lu2305xx.PubMedCrossRef
8.
Tikly M, Navarra SV: Lupus in the developing world–is it any different?. Best Pract Res Clin Rheumatol. 2008, 22 (4): 643-655. 10.1016/j.berh.2008.05.003.PubMedCrossRef
9.
Systemic lupus erythematosus - an update. Drug Ther Bull. 49 (7): 81-84.
10.
Nightingale AL, Farmer RD, de Vries CS: Incidence of clinically diagnosed systemic lupus erythematosus 1992–1998 using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf. 2006, 15 (9): 656-661. 10.1002/pds.1199.PubMedCrossRef
11.
Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ: Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum. 2007, 57 (4): 612-618. 10.1002/art.22683.PubMedCrossRef
12.
Adebajo AO: Low frequency of autoimmune disease in tropical Africa. Lancet. 1997, 349 (9048): 361-362.PubMedCrossRef
13.
Minaur N, Sawyers S, Parker J, Darmawan J: Rheumatic disease in an Australian aboriginal community in North Queensland Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004, 31 (5): 965-972.PubMed
14.
Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM, Ferraz MB: Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol. 2004, 31 (3): 594-597.PubMed
15.
Molokhia M, McKeigue PM, Cuadrado M, Hughes G: Systemic lupus erythematosus in migrants from west Africa compared with afro-caribbean people in the UK. Lancet. 2001, 357 (9266): 1414-1415. 10.1016/S0140-6736(00)04580-3.PubMedCrossRef
16.
Bae SC, Fraser P, Liang MH: The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis". Arthritis Rheum. 1998, 41 (12): 2091-2099. 10.1002/1529-0131(199812)41:12<2091::AID-ART2>3.0.CO;2-D.PubMedCrossRef
17.
Molokhia M, McKeigue P: Systemic lupus erythematosus: genes versus environment in high risk populations. Lupus. 2006, 15 (11): 827-832. 10.1177/0961203306070007.PubMedCrossRef
18.
Clatworthy MR, Willcocks L, Urban B, Langhorne J, Williams TN, Peshu N, Watkins NA, Floto RA, Smith KG: Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A. 2007, 104 (17): 7169-7174. 10.1073/pnas.0608889104.PubMedCentralPubMedCrossRef
19.
Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JO, Adler A, Alarcon-Riquelme ME, Gallant CJ, Boackle SA, Criswell LA, et al: Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011, 12 (4): 270-279. 10.1038/gene.2010.73.PubMedCentralPubMedCrossRef
20.
Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J: Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus. 2008, 17 (5): 371-375. 10.1177/0961203308089990.PubMedCrossRef
21.
Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH: Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun. 2004, 22 (2): 139-145. 10.1016/j.jaut.2003.11.003.PubMedCrossRef
22.
Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG: Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006, 65 (1): 57-63. 10.1136/ard.2005.035733.PubMedCentralPubMedCrossRef
23.
Savill J, Dransfield I, Gregory C, Haslett C: A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002, 2 (12): 965-975. 10.1038/nri957.PubMedCrossRef
24.
Matzinger P: The danger model: a renewed sense of self. Science. 2002, 296 (5566): 301-305. 10.1126/science.1071059.PubMedCrossRef
25.
26.
Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, et al: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med. 2005, 11 (2): 138-145. 10.1038/nm1176.PubMedCrossRef
27.
Marshak-Rothstein A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006, 6 (11): 823-835. 10.1038/nri1957.PubMedCrossRef
28.
von Landenberg P, Bauer S: Nucleic acid recognizing Toll-like receptors and autoimmunity. Curr Opin Immunol. 2007, 19 (6): 606-610. 10.1016/j.coi.2007.10.004.PubMedCrossRef
29.
Roth R, Nakamura T, Mamula MJ: B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. J Immunol. 1996, 157 (7): 2924-2931.PubMed
30.
Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006, 4 (7): 437-447. 10.1158/1541-7786.MCR-06-0007.PubMedCrossRef
31.
Tveita AA, Rekvig OP, Zykova SN: Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int. 2008, 74 (9): 1150-1158. 10.1038/ki.2008.308.PubMedCrossRef
32.
Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL: Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med. 1975, 59 (4): 533-552. 10.1016/0002-9343(75)90261-2.PubMedCrossRef
33.
34.
Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM: A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992, 35 (3): 311-318. 10.1002/art.1780350310.PubMedCrossRef
35.
Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA: Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 2005, 52 (4): 1138-1147. 10.1002/art.20999.PubMedCrossRef
36.
Hochberg MC: The application of genetic epidemiology to systemic lupus erythematosus. J Rheumatol. 1987, 14 (5): 867-869.PubMed
37.
Lawrence JS, Martins CL, Drake GL: A family survey of lupus erythematosus. 1. Heritability. J Rheumatol. 1987, 14 (5): 913-921.PubMed
38.
Deng Y, Tsao BP: Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010, 6 (12): 683-692. 10.1038/nrrheum.2010.176.PubMedCentralPubMedCrossRef
39.
Risch NJ: Searching for genetic determinants in the new millennium. Nature. 2000, 405 (6788): 847-856. 10.1038/35015718.PubMedCrossRef
40.
41.
Iles MM: What can genome-wide association studies tell us about the genetics of common disease?. PLoS Genet. 2008, 4 (2): e33-10.1371/journal.pgen.0040033.PubMedCentralPubMedCrossRef
42.
Altshuler D, Daly M: Guilt beyond a reasonable doubt. Nat Genet. 2007, 39 (7): 813-815. 10.1038/ng0707-813.PubMedCrossRef
43.
Kingsley CB: Identification of causal sequence variants of disease in the next generation sequencing era. Methods Mol Biol. 2011, 700: 37-46. 10.1007/978-1-61737-954-3_3.PubMedCrossRef
44.
Ramos PS, Williams AH, Ziegler JT, Comeau ME, Guy RT, Lessard CJ, Edberg JC, Zidovetzki R, Criswell LA, Gaffney PM, et al: Genetic analyses of interferon pathway-related genes reveals multiple new loci associated with systemic lupus erythematosus (SLE). Arthritis Rheum. 2011, 63 (7): 2049-2057. 10.1002/art.30356.PubMedCentralPubMedCrossRef
45.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008, 58 (1): 15-25. 10.1002/art.23177.PubMedCrossRef
46.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000, 25 (1): 25-29. 10.1038/75556.PubMedCentralPubMedCrossRef
47.
Zhou J, Wu R, High AA, Slaughter CA, Finkelstein D, Rehg JE, Redecke V, Hacker H: A20-binding inhibitor of NF-kappaB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein beta activation and protects from inflammatory disease. Proc Natl Acad Sci U S A. 2011, 108 (44): E998-E1006. 10.1073/pnas.1106232108.PubMedCentralPubMedCrossRef
48.
Yan K, Cao Q, Reilly CM, Young NL, Garcia BA, Mishra N: Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. J Biol Chem. 2011, 286 (33): 28833-28843. 10.1074/jbc.M111.233932.PubMedCentralPubMedCrossRef
49.
50.
Yu HH, Liu PH, Lin YC, Chen WJ, Lee JH, Wang LC, Yang YH, Chiang BL: Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus. 2010, 19 (10): 1219-1228. 10.1177/0961203310371152.PubMedCrossRef
51.
Glazier AM, Nadeau JH, Aitman TJ: Finding genes that underlie complex traits. Science. 2002, 298 (5602): 2345-2349. 10.1126/science.1076641.PubMedCrossRef
52.
53.
Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N, Qian XX, Tang Y, Lau YL, De Vries N, et al: A functional variant in microrna-146a promoter modulates its expression and confers disease risk for Systemic Lupus Erythematosus. PLoS Genet. 2011, 7 (6): e1002128-10.1371/journal.pgen.1002128.PubMedCentralPubMedCrossRef
54.
Wong KK, de Leeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, MacAulay C, Ng RT, Brown CJ, Eichler EE, et al: A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet. 2007, 80 (1): 91-104. 10.1086/510560.PubMedCentralPubMedCrossRef
55.
Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, Hebert M, Jones KN, Shu Y, Kitzmiller K, et al: Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet. 2007, 80 (6): 1037-1054. 10.1086/518257.PubMedCentralPubMedCrossRef
56.
Walport MJ: Complement. First of two parts. N Engl J Med. 2001, 344 (14): 1058-1066. 10.1056/NEJM200104053441406.PubMedCrossRef
57.
Ptacek T, Li X, Kelley JM, Edberg JC: Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus. Cytogenet Genome Res. 2008, 123 (1–4): 142-147.PubMedCrossRef
58.
Thai TH, Christiansen PA, Tsokos GC: Is there a link between dysregulated miRNA expression and disease?. Discov Med. 2010, 10 (52): 184-194.PubMed
59.
Dai R, Ahmed SA: MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011, 157 (4): 163-179. 10.1016/j.trsl.2011.01.007.PubMedCentralPubMedCrossRef
60.
Nelson P, Kiriakidou M, Sharma A, Maniataki E, Mourelatos Z: The microRNA world: small is mighty. Trends Biochem Sci. 2003, 28 (10): 534-540. 10.1016/j.tibs.2003.08.005.PubMedCrossRef
61.
Davidson-Moncada J, Papavasiliou FN, Tam W: MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci. 2010, 1183: 183-194. 10.1111/j.1749-6632.2009.05121.x.PubMedCentralPubMedCrossRef
62.
Wahid F, Shehzad A, Khan T, Kim YY: MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010, 1803 (11): 1231-1243. 10.1016/j.bbamcr.2010.06.013.PubMedCrossRef
63.
64.
65.
Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, Xu ZM, Yin YB: Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007, 16 (12): 939-946. 10.1177/0961203307084158.PubMedCrossRef
66.
Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y: Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009, 29 (7): 749-754. 10.1007/s00296-008-0758-6.PubMedCrossRef
67.
Te JL, Dozmorov IM, Guthridge JM, Nguyen KL, Cavett JW, Kelly JA, Bruner GR, Harley JB, Ojwang JO: Identification of unique microRNA signature associated with lupus nephritis. PLoS One. 2010, 5 (5): e10344-10.1371/journal.pone.0010344.PubMedCentralPubMedCrossRef
68.
Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X, Li J, Zhou H, Tang Y, Shen N: MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010, 184 (12): 6773-6781. 10.4049/jimmunol.0904060.PubMedCrossRef
69.
Stagakis E, Bertsias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, Iliopoulos D, Boumpas DT: Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis. 2011, 70 (8): 1493-1506.CrossRef
70.
Zhao S, Wang Y, Liang Y, Zhao M, Long H, Ding S, Yin H, Lu Q: MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 2011, 63 (5): 1376-1386. 10.1002/art.30196.PubMedCrossRef
71.
Lashine YA, Seoudi AM, Salah S, Abdelaziz AI: Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin Exp Rheumatol. 2011, 29 (2): 351-357.PubMed
72.
Hai-yan W, Yang L, Mei-hong C, Hui Z: Expression of MicroRNA-146a in peripheral blood mononuclear cells in patients with systemic lupus Erythematosus. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011, 33 (2): 185-188.PubMed
73.
Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, et al: MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60 (4): 1065-1075. 10.1002/art.24436.PubMedCrossRef
74.
Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC, Li PK, Szeto CC: Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol. 2010, 37 (12): 2516-2522. 10.3899/jrheum.100308.PubMedCrossRef
75.
Divekar AA, Dubey S, Gangalum PR, Singh RR: Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol. 2011, 186 (2): 924-930. 10.4049/jimmunol.1002218.PubMedCentralPubMedCrossRef
76.
Ando Y, Maida Y, Morinaga A, Burroughs AM, Kimura R, Chiba J, Suzuki H, Masutomi K, Hayashizaki Y: Two-step cleavage of hairpin RNA with 5' overhangs by human DICER. BMC Mol Biol. 2011, 12: 6-10.1186/1471-2199-12-6.PubMedCentralPubMedCrossRef
77.
Hikami K, Kawasaki A, Ito I, Koga M, Ito S, Hayashi T, Matsumoto I, Tsutsumi A, Kusaoi M, Takasaki Y, et al: Association of a functional polymorphism in the 3'-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum. 2011, 63 (3): 755-763. 10.1002/art.30188.PubMedCrossRef
78.
Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. Adv Immunol. 1985, 37: 269-390.PubMedCrossRef
79.
Morel L: Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol. 2010, 6 (6): 348-357. 10.1038/nrrheum.2010.63.PubMedCrossRef
80.
Wakeland EK, Liu K, Graham RR, Behrens TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity. 2001, 15 (3): 397-408. 10.1016/S1074-7613(01)00201-1.PubMedCrossRef
81.
Blake JA, Bult CJ, Kadin JA, Richardson JE, Eppig JT: The Mouse Genome Database (MGD): premier model organism resource for mammalian genomics and genetics. Nucleic Acids Res. 2011, 39 (Database issue): D842-D848.PubMedCentralPubMedCrossRef
82.
Xu Z, Morel L: Genetics of systemic lupus erythematosus: contributions of mouse models in the era of human genome-wide association studies. Discov Med. 2010, 10 (50): 71-78.PubMed
83.
Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O, Ahmed SA: Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One. 2010, 5 (12): e14302-10.1371/journal.pone.0014302.PubMedCentralPubMedCrossRef
84.
Camon E, Magrane M, Barrell D, et al: The Gene Ontology Annotation (GOA) Database: sharing knowledge in Uniprot with Gene Ontology. Nucleic Acids Res. 2004, 32 (Database issue): D262-6.PubMedCentralPubMedCrossRef
85.
Beissbarth T, Speed TP: GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004, 20 (9): 1464-5. 10.1093/bioinformatics/bth088.PubMedCrossRef
86.
Zhao X, Tang Y, Qu B, et al: MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 2010, 62 (11): 3425-35. 10.1002/art.27632.PubMedCrossRef
Metadata
Title
A diverse array of genetic factors contribute to the pathogenesis of Systemic Lupus Erythematosus
Authors
Nicki Tiffin
Adebowale Adeyemo
Ikechi Okpechi
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2013
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-8-2

Other articles of this Issue 1/2013

Orphanet Journal of Rare Diseases 1/2013 Go to the issue

Review

Guideline of transthyretin-related hereditary amyloidosis for clinicians

Review

Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area

Research

Characteristics and management of congenital esophageal stenosis: findings from a multicenter study

Research

Drug development for exceptionally rare metabolic diseases: challenging but not impossible

Research

Genotype-phenotype correlations in recessive RYR1-related myopathies

Research

Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study